Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer

Status: No longer recruiting

Protocol number: BO16348

Sponsor: F Hoffman-La Roche Ltd

Company division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of Herceptin on disease-free and overall survival in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy

Brief summary: This study will compare the efficacy and safety of different treatment durations of intravenous Herceptin compared to observation (no treatment) in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy. The anticipated time on study treatment is 2+ years, and the target sample size is 500+ individuals. Target sample size is 4482.

Study phase: III

Study type: Interventional; Treatment; Randomized; Open Label; Placebo; Parallel; Safety/Efficacy study

Condition: Breast Cancer

Intervention type: Drug

Intervention name: trastuzumab[Herceptin]

Primary outcome: 1. Disease-free survival

Key secondary outcomes: 1. Efficacy: Overall survival, relapse-free survival, distant disease-free survival. Safety: Adverse events, with special emphasis on cardiac safety, laboratory parameters.

Inclusion criteria:

  • female patients, >=18 years of age, with HER2-positive primary breast cancer;
  • completion of adjuvant systemic chemotherapy and radiotherapy, if applicable.

Exclusion criteria:

  • history of prior invasive breast cancer;
  • prior use of any anti-HER2 therapy.

Gender: Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Anticipated start date: December, 2001

Trial registration date: 06/24/2005

Date last updated: 8/19/2008


Link to trial result

This trial was conducted at the following locations:

Argentina

  • Buenos Aires

Australia

  • Adelaide
  • Fitzroy
  • Frankston
  • Geelong
  • Heidelberg
  • Liverpool
  • Melbourne
  • Parkville
  • Perth
  • Sydney
  • Toowoomba
  • Waratah
  • Wodonga

Austria

  • Bludesch
  • Graz
  • Innsbruck
  • Klagenfurt
  • Linz
  • Salzburg
  • St Veit an der Glan
  • Villach
  • Vöcklabruck
  • Wels
  • Wien
  • Wiener Neustadt

Belgium

  • Antwerpen
  • Baudour
  • Bruxelles
  • Charleroi
  • Kortrijk
  • Leuven
  • Liege
  • Namur
  • Oostende
  • Verviers

Brazil

  • Porto Alegre
  • Rio De Janeiro
  • Santo Andre

Canada

  • Calgary, AB
  • Kelowna, BC
  • Surrey, BC
  • Vancouver, BC
  • Victoria, BC
  • Winnipeg, MB
  • Mississauga, ON
  • Sault Ste Marie, ON
  • St. Catharines, ON
  • Toronto, ON
  • Windsor, ON
  • Charlottetown, PE
  • Quebec City, QC
  • Regina, SK
  • Saskatoon, SK

Chile

  • Santiago

China

  • Beijing
  • Guangzhou
  • Hangzhou
  • Hong Kong
  • Shanghai
  • Wuhan

Costa Rica

  • San José

Croatia

  • Split
  • Zagreb

Denmark

  • Aalborg
  • Esbjerg
  • Herlev
  • Herning
  • Hillerød
  • København
  • Naestved
  • Odense
  • Roskilde
  • Sønderborg
  • Vejle
  • Viborg

France

  • Caen
  • Limoges
  • Metz

Germany

  • Augsburg
  • Bad Saarow
  • Bayreuth
  • Berlin
  • Bonn
  • Bremen
  • Celle
  • Chemnitz
  • Dortmund
  • Dresden
  • Duisburg
  • Düsseldorf
  • Erlangen
  • Essen
  • Esslingen
  • Frankfurt Am Main
  • Freiburg
  • Fulda
  • Georgsmarienhütte
  • Göttingen
  • Greifswald
  • Halle
  • Hamburg
  • Hameln
  • Hamm
  • Hannover
  • Heidelberg
  • Herne
  • Ibbenbueren
  • Jena
  • Kaiserslautern
  • Karlsruhe
  • Kassel
  • Kiel
  • Köln
  • Krefeld
  • Kronach
  • Lemgo
  • Leonberg
  • Leverkusen
  • Lübeck
  • Mannheim
  • Minden
  • München
  • Münster
  • Oberhausen
  • Oldenburg
  • Potsdam
  • Quedlinburg
  • Rheinfelden
  • Rostock
  • Rotenburg-Wuemme
  • Rottweil
  • Saarbrücken
  • Stuttgart
  • Trier
  • Tübingen
  • Ulm
  • Wiesbaden
  • Witten
  • Würzburg

Greece

  • Heraklion

Guatemala

  • Guatemala City

Hungary

  • Budapest
  • Kecskemet
  • Szeged

Ireland

  • Cork

Israel

  • Ashkelon
  • Beer Sheva
  • Haifa
  • Holon
  • Jerusalem
  • Kfar Saba
  • Nahariya
  • Petah Tikva
  • Ramat Gan
  • Rehovot
  • Safed
  • Tel Aviv
  • Zerifin

Italy

  • Alba
  • Ancona
  • Arezzo
  • Aviano
  • Bergamo
  • Biella
  • Bologna
  • Bolzano
  • Brescia
  • Cagliari
  • Camposampiero
  • Carpi
  • Casalpusterlengo
  • Castelfranco Veneto
  • Como
  • Cosenza
  • Cuneo
  • Fano
  • Firenze
  • Genova
  • Lecco
  • Legnano
  • Livorno
  • Lucca
  • Mantova
  • Milano
  • Modena
  • Napoli
  • Noale
  • Padova
  • Palermo
  • Parma
  • Pavia
  • Perugia
  • Pisa
  • Ragusa
  • Reggio Emilia
  • Rionero in Vulture
  • Roma
  • Rozzano
  • San Giovanni Rotondo
  • Sassari
  • Segrate
  • Siena
  • Thiene
  • Torino
  • Trento
  • Trieste
  • Udine
  • Varese
  • Vecchiazzano
  • Venezia
  • Vicenza

Japan

  • Aichi
  • Chiba
  • Kanagawa
  • Matsuyama-Shi, Ehime
  • Tochigi
  • Tokyo

Korea, Republic of

  • Seoul

Mexico

  • Chihuahua
  • Guadalajara
  • Merida
  • Mexicali
  • Mexico City
  • Monterrey
  • Obregon

Netherlands

  • Amsterdam
  • Leiden
  • Maastricht
  • Rotterdam
  • Sittard
  • Utrecht

New Zealand

  • Auckland
  • Christchurch
  • Dunedin
  • Palmerston North
  • Wellington

Norway

  • Oslo
  • Tromsø

Panama

  • Panama City

Poland

  • Gdansk
  • Gliwice
  • Krakow
  • Lodz
  • Poznan
  • Warszawa

Portugal

  • Coimbra
  • Faro
  • Lisboa
  • Porto
  • Setubal

Russian Federation

  • Barnaul
  • Kazan
  • Moscow
  • St Petersburg

Singapore

  • Singapore

Slovakia

  • Banska Bystrica
  • Bratislava
  • Zilina

South Africa

  • Cape Town
  • Durban
  • Johannesburg
  • Lynnwood
  • Sandton

Spain

  • Alzira
  • Barcelona
  • Caceres
  • Cádiz
  • Guadalajara
  • Huelva
  • Jaen
  • La Coruna
  • La Laguna
  • Las Palmas de Gran Canaria
  • Lleida
  • Madrid
  • Malaga
  • Mataro
  • Navarra
  • Orense
  • Oviedo
  • Palma de Mallorca
  • Pontevedra
  • Sabadell
  • Santa Cruz de Tenerife
  • Sevilla
  • Terrassa
  • Toledo
  • Valencia
  • Vigo
  • Zaragoza

Sweden

  • Gaevle
  • Linkoeping
  • Lund
  • Malmoe
  • Molndal
  • Stockholm
  • Umea
  • Uppsala
  • Västerås

Switzerland

  • Aarau
  • Basel
  • Bern
  • Chur
  • Lausanne
  • Mendrisio
  • St Gallen
  • Zürich

Taiwan

  • Changhua
  • Kaohsiung
  • Taichung
  • Tainan
  • Taipei
  • Taoyuan

Thailand

  • Bangkok

United Kingdom

  • Aberdeen
  • Belfast
  • Birmingham
  • Blackpool
  • Bournemouth
  • Brighton
  • Bristol
  • Cambridge
  • Cardiff
  • Chelsmford
  • Cheltenham
  • Colchester
  • Dundee
  • East Kilbride
  • Edinburgh
  • Epping
  • Exeter
  • Glasgow
  • Huddersfield
  • Hull
  • Ipswich
  • Kilmarnock
  • Kings Lynn
  • Lancaster
  • Leeds
  • London
  • Manchester
  • Merseyside
  • Middlesborough
  • Middlesex
  • Newcastle upon Tyne
  • Oxford
  • Peterborough
  • Portsmouth
  • Preston
  • Romford
  • Salisbury
  • Scunthorpe
  • Sheffield
  • Shrewsbury
  • Southampton
  • Stoke-on-Trent
  • Sutton
  • Swansea
  • Torquay
  • Westcliffe-on-Sea
  • Wolverhampton
  • Worthing
  • Yeovil
  • York

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply